Myeloma
Late-breaking phase 3 data presented at ASCO 2026 highlight mezigdomide, an oral CELMoD, as a potential new option for patients with relapsed/refractory multiple myeloma previously exposed to anti-CD38 monoclonal antibodies and lenalidomide.
Isatuximab is a CD38-receptor targeted monoclonal antibody approved as a combination therapy for the treatment of RRMM in patients who have received 1 to 3 lines of prior therapy.
In proud collaboration with EBMT, we have captured the highlights from the recent 52nd Annual Meeting, EBMT 2026. Below, hear from Dr Anna Sureda, President of EBMT, Dr Rafael Duarte, Congress President, and other world-leading experts sharing some of the most ...
At EBMT26, Prof Meral Beksac discusses data from the phase III PERSEUS trial, where adding daratumumab to standard VRd induction and consolidation – followed by daratumumab–lenalidomide maintenance – has delivered striking gains in sustained MRD negativity and progression-free survival. The findings reinforce a shift toward quadruplet therapy as the new standard of care in TE NDMM.
We often focus on clinical excellence, but spend less time developing broader skills that could help us better lead with purpose and build more fulfilling, impactful careers. In this episode, part of a mini-series in partnership with LEADderm, Dr Jennifer Soung and Denise Mann explore how clinicians can engage with the media to educate, empower and extend their impact beyond the clinic.
Key takeaways Primary endpoint not met, but promising trends observed – The Galleri® test did not achieve a statistically significant reduction in combined Stage III–IV cancer diagnoses, but showed favourable shifts toward earlier detection in 12 high-risk cancers. Reduction in late-stage ...
The 67th ASH Annual Meeting and Exposition brought over 30,000+ attendees, 5,000+ novel abstracts and 275+ exhibitors corporate supporters, academic leaders and patient-advocacy groups. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of haematology practice.
Discover the practice-changing data shaping the future of myeloma, chronic lymphocytic leukemia and small lymphocytic lymphoma. Our ASH25 coverage highlights the pivotal Majestec-3 results, emerging CAR T-cell innovations, and the landmark BRUIN CLL-313 trial poised to redefine first-line therapy. With expert commentary from Prof. Meletios-Athanasios Dimopoulos, this in-depth analysis uncovers what these breakthroughs mean for clinical practice.
Learn more about the six highly anticipated late-breaking abstracts at ASH 2025. From in-vivo CAR-T technology and novel ITP strategies to genomic diagnostics and pragmatic perioperative trials. These data showcase fresh, innovative research, potential practice shifts and early signals that we will all want to follow closely.
The European Hematology Association (EHA) has released its official EHA Perspectives in Hematology reports from the 2025 Annual Congress in Milan, now available in two separate editions covering malignant and non-malignant hematology. Following strong interest in the 2024 pilot report, this expanded format offers deeper insights into scientific and clinical advances across the field.
As touchHAEMATOLOGY approaches 20 years of providing education for busy haematologists, we are looking to the future—and it certainly looks bright!
At #EHA2025, Dr Shaji Kumar presented encouraging results from a phase II trial of teclistamab and talquetamab in extramedullary multiple myeloma. The bispecific combination achieved an 80% response rate and 55% complete responses, offering a promising new option for this aggressive, high-risk disease with limited treatment success to date.
At #EHA2025, Dr Gurbaksh Kaur presented updated results from the iMMagine-1 trial of AnitoCell, a BCMA-targeted CAR T therapy. With a 97% response rate and manageable safety, the D-domain construct shows early promise in relapsed/refractory myeloma. Kaur discusses efficacy, neurotoxicity, sequencing questions and where the field is headed next.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
